

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: BioMark Diagnostics Inc. (the "Issuer").

Trading Symbol: BUX

Number of Outstanding Listed Securities: 76,784,229

Date: April 1, 2021

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered, nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

The Issuer continued its business of developing proprietary, non-invasive, and accurate cancer diagnostic solutions which can help detect, monitor, and assess treatment for cancer early, accurately and cost effectively.

2. Provide a general overview and discussion of the activities of management.
 - **The new wave of COVID-19 variants is causing extended delays in clinical trial activities with newly announced lockdowns. Most of our clinical partner centres halted oncology related trials over the past 9 months were slowly re-opening specific trials at CancerCare Manitoba, IUCPQ (Quebec) and in China. We there will not be extended closure due to upswing in covid cases. Financial, operational and recovery measures instituted by the management team aided in sustaining business viability over the past 12 months. Financial measures include reducing working capital, delaying capital expenditures(equipment), cost cutting initiatives and tapping into government grants/support programs.**
 - **On March 2, 2021, BioMark announced that it has granted 2,100,000 incentive stock options under the Company's Stock Option Plan ("Option Plan") to third-party consultants to support market communication and corporate strategy as it advances its commercialization efforts. Each option is exercisable into one common share at a price of \$0.25 per share and will vest immediately. The options will expire two years from the date of grant. All other terms and conditions of options are in accordance with the terms of the Company's Stock Option Plan.**
 - **On March 16, 2021, BioMark was pleased to announce today that its sponsored research collaboration with The Metabolomics Innovation Centre (TMIC) was successful in receiving funding from the Novel Technology Application in Cancer Prevention and Early Detection Spark Grants competition. This comes after the organizers of the competition, the Canadian Cancer Society/Canadian Institutes of**

Health Research - Institute of Cancer Research, and Brain Canada Foundation, evaluated the full proposal for its relevance to funding opportunities in the prevention and early detection of cancer. The funding application is entitled "A novel rapid, liquid biopsy early-stage lung cancer diagnostic test". The grant was for \$150,000.

- IUCPQ and BioMark completed a CQDM's *SyneriQc* Application titled "Development and Evaluation of a Multimodal Approach to Predict Lung Cancer Risk and Determine EGFR Mutation Profile in a Lung Cancer Screening Population". The application is for a total grant of \$3.5 million and will involve several leading investigators and other leading biopharma. The decision is expected to be announced later in June or July of 2021. The application was submitted on March 18, 2021.
- On March 31, 2021, the article "Use of Amantadine in the Evaluation of Response to Chemotherapy in Lung Cancer - a Pilot Study" has been published in April issue of Future Science OA. Citation is Future Science OA, vol 7 No. 4 (2021) FSO679. The article is available on PubMed as well.
- In December 2020, BioMark was informed that the project titled "A Pan Canadian initiative for the development of liquid biopsy assay for lung cancer screening" has been approved unconditionally by MEDTEQ+ Scientific Committee and that decision has been confirmed by MEDTEQ+ Board. The project will then go to Ministère de l'Économie et de l'Innovation (MEI) for final approval. The project is centred around the active collaboration between Phytronix Technologies Inc, IUCPQ, The Metabolomics Innovation Centre (TMIC) and Saint Boniface Research Hospital. Decision is imminent
- GuangDong Longhu Sci.&Tech. Company Limited and BioMark are planning to amend the LOI signed in Nov 2019 to reflect the impact that the pandemic made to the planned research activities. Both parties are looking at a reset date targeted April 15, 2021 where trials can commence, and milestone payment terms as stated in the LOI based on successful clinical trials. BioMark's legal counsel is reviewing the amendments.

- **Bio-Stream Diagnostics continues to refine its rapid Raman spectroscopy Covid-19 pandemic screening platform and anticipates to further involve scientists from National Research Council of Canada Institute for Biodiagnostics (NRC-IBD) and Laval. In addition, new apps are being developed by software specialists.**

About MEDTEQ+

MEDTEQ+'s mission is, through collaborative, industry led projects, to accelerate innovation and position, on a global scale, products and services developed by the Canadian medical technologies industry, thereby generating major economic impacts while improving healthcare systems for the ultimate benefit of patients in Canada and around the world.

With a dual provincial and federal mandate, MEDTEQ+ continues to be a focus point for Canada's medical technology sector in terms of research, innovation and the integration of leading-edge solutions in the delivery of health care.

About Sparks Grant.

BioMark would like to thank The Canadian Cancer Society (CCS), the Canadian Institutes of Health Research - Institute of Cancer Research (CIHR-ICR), and Brain Canada Foundation for their generous financial support for Spark Grants on the Application of Disruptive Technologies in Cancer Prevention and Early Detection of the Canadian Cancer Society and the Canadian Institutes of Health Research-Institute for Cancer Research and Brain Canada Foundation (CCS grant # 707073/CIHR-IRSC grant # 0590008438). Both TMIC and BioMark will acknowledge all the supporting agencies in publications or events related to the use of the funds.

About TMIC

The Metabolomics Innovation Centre (TMIC) is a nationally funded network that offers a unique combination of infrastructure and expertise to perform a wide range of cutting-edge metabolomic studies for clinical trials research, biomedical studies, bioproducts studies, nutrient profiling and environmental testing. Network scientists include Dr. Liang Li (University of Alberta), Dr. David Wishart (University of Alberta), Dr. Christoph Borchers (McGill University), Dr. James

Harynuk (University of Alberta), Dr. Michael Overduin (University of Alberta), Dr. David Goodlett (University of Victoria), Dr. Philip Britz-McKibbin (McMaster University) and Dr. Ian Lewis (University of Calgary).

TMIC has access to more than \$26 million in state-of-the-art metabolomics infrastructure. It is supported by a team of lab managers, NMR spectroscopists, mass spectrometrists, chemists, computer scientists, statisticians and bioinformaticians. TMIC is capable of identifying and quantifying up to 2000 different chemicals from certain biological samples. This is approximately 5X more comprehensive than any other service currently available.

About CQDM's SynergiQc program

The program is designed to promote university-based industrial research in the biopharmaceutical field that will generate economic benefits for Quebec.

More information is available at <https://cqdm.org/en/synergiqc-2/>

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

Not applicable.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

Not applicable.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

Not applicable.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

Not applicable.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

Not applicable.

8. Describe the acquisition of new customers or loss of customers.

Not applicable.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trademarks.

The Issuer continues to file trademark and patents in specific jurisdictions for all its patents. Review of the filings and opinions from patent offices are being reviewed as needed.

10. Report on any employee hiring, terminations or lay-offs with details of anticipated length of lay-offs.

Not applicable.

11. Report on any labour disputes and resolutions of those disputes if applicable.

Not applicable.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

Not applicable.

FORM 7 – MONTHLY PROGRESS REPORT

January 2015

Page 6

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

Not applicable.

14. Provide details of any securities issued and options or warrants granted.

On March 2, 2021, the issuer granted 2,100,000 incentive stock options under the Company's Stock Option Plan to third-party consultants. Each option is exercisable into one common share at a price of \$0.25 per share and will vest immediately.

On March 9, 2021, 2,000,000 shares have been issued upon the exercise of the options by the option holder at a price of \$0.25 per share, upon and subject to the terms and condition.

On March 22, 2021, 810,000 shares have been issued upon the exercise of the warrants by the warrant holder at a price of \$0.20 per share, upon and subject to the terms and condition.

15. Provide details of any loans to or by Related Persons.

Not applicable.

16. Provide details of any changes in directors, officers, or committee members.

Not applicable.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The trends and risks which are likely to impact the Issuer are discussed in the Form 51-102F1 Management's Discussion & Analysis Annual Report for the Year Ended March 31, 2020.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there where is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated April 1, 2021.

Rashid Ahmed Maula Bux
Name of Director or Senior Officer

"Rashid Ahmed Maula Bux"
Signature

President & CEO
Official Capacity

Issuer Details	For Month End	Date of Report
Name of Issuer	March, 2021	YY/MM/DD
BioMark Diagnostics Inc.		2021/04/01
Issuer Address		
130 - 3851 Shell Road		
City/Province/Postal Code	Issuer Fax No.	Issuer Telephone No.
Richmond, BC, V6X 2W2	N/A	(604) 370-0779
Contact Name	Contact Position	Contact Telephone No.
Rashid Ahmed Bux	CEO	(604) 370-0779
Contact Email Address	Web Site Address	
info@biomarkdiagnostics.com	www.biomarkdiagnostics.com	

FORM 7 – MONTHLY PROGRESS REPORT

January 2015